Develops drugs for chronic inflammatory diseases.
Jun 2026Revenue $10.0M/yrExpenses $112M/yr
No trendCash runway ≈ 2.7 years from Jun 2026
Figures by year
When will Evommune be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Jun 2026, revenue was $10.0M and expenses $112M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $13.0M | $94.1M | −$81.1M |
| Dec 2024 | $7.00M | $77.0M | −$70.0M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.